Faculty
Sadako Akashi-Tanaka, M.D., Ph.D.
EDUCATION :
Medical School : School of Medicine, University of Tokyo
Tokyo, Japan. 1984-1990
Graduated School: School of Medicine, University of Tokyo, Japan.(1999)
POSTGRADUATE TRAINING :
May 1990 – May 1992 Resident, The Third Department of Surgery, Univ. of Tokyo (Professor : Dr. Takeshi Oohara).
June 1992 – May 1995 Resident, Department of Surgery, National Cancer Center Hospital, Tsukiji, Tokyo, Japan.
June 1995 – March 1996 Chief Resident, Division of Breast Surgery, the same as above
PROFESSIONAL CAREER
April 1996 – September 2008 Attending surgeon, Division of Breast Surgery, the same as above
October 2008 –September 2011 Chief, Division of Breast Surgery, the same as above
October 2011 – present, Associate professor, Department of Breast Surgical Oncology, Showa University
MEMBERSHIP OF ACADEMIC SOCIETIES
Japan Surgical Society Trainer
Members of the Medical Terminology Committee
Members of the Committee for Improvement of Surgeons’ Work Environment
Members of the Committee for Gender Equality
Japanese Breast Cancer Society Councilor, Trainer
Japan Surgical Association, Councilor, Editorial Board
embers of the domestic surgical training Committee
Japan Society of Clinical Oncology
Members of the Supervisory Committee on Cancer Clinical Practice Guideline
The Japan association of breast and thyroid sonography (JABTS)
President of the 40th meeting of the JABTS
Executive Director. Head of Secretariat
The Japanese HBOC consortium, Councilor, Member of academic committee
Japan Association of Women Surgeons Manager
Award
4th Japanese Breast Cancer Association Merit Award
Best Doctors in Japan (2006～)
Research Fields
Diagnosis images for breast cancer surgery
Preoperative chemotherapy for breast cancer
Preoperative endocrine therapy for breast cancer
Precision medicine for breast cancer
Dr Hiroko Bando is Associate Professor of Breast and Endocrine Surgery at the University of Tsukuba, in Ibaraki, Japan. She has completed her surgical training at Tokyo Metropolitan Komagome Hospital, and received PhD degree from Tokyo Medical and Dental University, graduate school of medicine. She is specialized in breast and endocrine oncology, and her clinical work focuses on the treatment of breast disease. Her team has special interests in the holistic management of breast cancer with multidisciplinary approach. Her recent activity includes exploring the supporting program for young breast cancer patients and survivors. Together with the basic scientists’ team in her institute, she is also actively involved in defining the tumor angiogenesis mechanism, and optimal treatment theory for breast cancer stem cells.
Ian Campbell is currently a Consultant Surgeon at Waikato Hospital and an Associate Professor with the Waikato Clinical School, University of Auckland Medical School. He has subspecialised in the management of breast cancer over the last 25 years and has Chaired a number of national committees on breast cancer management and standards of care in NZ, including the NZ Guidelines Group: Management of Early Breast Cancer published by the NZ Ministry of Health in 2009, and the National Breast Cancer Work Group responsible for developing Standards of Service Provision for Breast Cancer, published 2013.
He is very actively involved in clinical research across the spectrum from prevention to better treatment and quality of life. A particular interest is in sentinel node biopsy and management of the axilla, and he is a member of the SNAC Trial Executive and Co-Chair of the SNAC2 Trial. Ian is a long standing member of the ANZ Breast Cancer Trials Group Scientific Advisory Committee, previous Chair of the Local therapy subcommittee, and previous NZ member on the ANZBCTG Board.
Dr. Caudle is an associate professor of breast surgical oncology at the University of Texas MD Anderson Cancer Center. Her research has centered on the surgical management of nodal disease in breast cancer, specifically the development of targeted axillary dissection, a novel surgical technique that improves axillary node staging after neoadjuvant chemotherapy. She also has research interests focusing on improving quality in breast cancer surgery and methods for improving dissemination and implementation of clinical trial data.
Prof. Arlene Chan graduated from the medical school of University of Melbourne, Australia and obtained her Fellowship in Medical Oncology from the Royal Australasian College of Physicians and a Masters of Medicine in Palliative Care from the University of Melbourne.
She received a fellowship in breast cancer/cancer genetics from Princess Margaret Hospital, Toronto before returning to Australia as a Consultant Medical Oncologist at Royal Perth Hospital. She has been a breast cancer-specific oncologist at the Mount Hospital since 1999. She is a professor at the Curtin Health Innovation Research Institute, Curtin University and the Director of the breast clinical trials unit at the Mount Hospital. She is a founding member of the Breast Cancer Research Centre – WA (a clinician driven, not-for-profit charitable breast cancer research group based in Perth) and serves as the Vice-Chair. She is a member of the academic steering committee of several breast cancer trials, has been an invited speaker to more than 130 national and international meetings on breast cancer and has authored more than 100 publications. Her interests include clinical research in understanding biological determinants of therapeutic response, optimizing symptomatic care in early and advanced breast cancer and developing data collection systems for clinical research and measuring patient outcomes.
Dr. Sanjoy Chatterjee works as a senior consultant clinical oncologist at Tata Medical Center, Kolkata, India, his team seeing around 700 new breast cancer cases every year. Having trained as a clinical oncologist in the UK, Dr Chatterjee was a consultant clinical oncologist treating breast cancer at Newcastle upon Tyne, UK. Dr Chatterjee is currently a PI in studies testing radiation fractionations in breast cancer and co-investigator in sponsored international Phase III studies in targeted therapy in breast cancer.
Dr. Stephen Chia is currently co-chair of the Breast Disease Site of the Canadian Cancer Trials Group, a member of the CCTG Breast Executive Committee, the CCTG IND Executive Committee, and the CCTG Breast Correlative Science Committee. He is also a member of the NCI (National Cancer Institute) Breast Cancer Steering Committee of the NIH (US) sponsored NCTN (National Clinical Trials Network). He was a past member of the American Society of Clinical Oncology (ASCO) Scientific Committee (2009 to 2012), ASCO Breast Symposium Committee (2014-2015) and served as the Breast Track chair (Triple Negative/Cytotoxic/Local) for the ASCO 2011 Annual Meeting. He is an active researcher in phase 1 to 3 trials in breast cancer and investigational new drugs. He has an established interest in neoadjuvant systemic therapy for breast cancer and drug development and spearheaded the efforts for the BCCA – VCC to be the first Canadian site for the I-SPY2 consortium. He is currently carrying out clinical and translational studies in breast cancer with peer-reviewed, grant-funded research from the NCIC, National Institutes of Health (USA), Canadian Breast Cancer Research Alliance, and the Canadian Breast Cancer Foundation.
He is widely published (137 peer-reviewed publications) in international peer-reviewed journals including high impact journals such as the Journal of Clinical Oncology, Lancet, the Journal of the National Cancer Institute, Cell, Annals of Oncology, JAMA Oncology, Clinical Cancer Research and Nature. He has written Commentaries in Lancet (twice) for the EBCTCG Overviews (2011 and 2005), and in Lancet Oncology for the NOAH study (2010), GEPARQUINTO study (2012), and the BOLERO-3 study (2014) respectively. He is also a Subject Editor for the British Journal of Cancer (Jan 2015)[impact factor 5.908] as well as being on the Up-To-Date editorial roster (Metastatic breast cancer: Prognostic/Predictive section).
Louis Chow is Executive Director of the Organization for Oncology and Translational Research in Hong Kong; a distinguished professor of Macau Science Technology; a Medical Director of the Comprehensive Centre for Breast Diseases at the UNIMED Medical Institute in Hong Kong, an honorary professor of the Third Military Medical University; an honorary professor at Ningxia Medical College School of Clinical Medicine in Ningxia, China; an honorary professor at Tohoku University in Sendai, Japan; visiting professor at Wuhan University of Science and Technology; and an honorary consultant of Kiang Wu Hospital in Macau. Professor Chow was the immediate past honorary clinical professor of the clinical trials centre at The University of Hong Kong, past president of the Asian Breast Cancer Society, and former honorary secretary of The Hong Kong Academy of Medicine.
Professor Chow is an expert in cancer research and has obtained a patent on a mouse cell line derived from human malignant cystosarcoma phylloides. In the past few years, he has obtained various research and professional grants for cancer research purposes in the university and contributed as Principal Investigator/Co-investigator of several international clinical trials. Professor Chow has published more than 190 articles in peer-reviewed journals. His key research interests are breast cancer molecular therapy, chemoresistance, chemoprevention and translational research in breast cancer.
Professor Chow was awarded The Kim Hyun-Jib Breast Cancer Research Memorial Award in 2012.
Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specialising in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associated Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr. Cortés was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. Since 2003, he has worked in the Department of Medical Oncology at the Hospital Vall d’ Hebron, Barcelona, where he is Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in New Drugs Development. Dr. Cortés is Head of the Breast Cancer Unit and the Melanoma Unit.
In addition, he has two masters’ degree: “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.
Dr. Cortes is the author of more than 100 publications, especially about breast tumours and new drugs and more than 250 communications at different conferences. He actively participates in the development of numerous national and international clinical investigations, especially in relation to drugs directed against molecular targets and new chemotherapy agents, and he is an ad hoc reviewer of various oncology journals.
Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), a member of the Scientific Committee of the European Society of Medical Oncology and the Scientific Committee of SOLTI group.
Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.
Dr. Han received his MD and PhD degrees from the Seoul National University (SNU) College of Medicine, Korea. He has started faculty appointment in SNU since 2004. Starting from 2015, he has become a Professor of SNU College of Medicine. He is an active member of AACR and ASCO. He is an associate editor of Journal of Breast Cancer and BMC Research Notes, and editorial board of Breast Cancer. He has been devoted to both breast cancer patient care and research. He has published more than 240 original articles in peer reviewed journals, including Journal of Clinical Oncology, Annals of Surgery, Annals of Oncology, Clinical Cancer Research, Cancer, and Breast Cancer Research. His clinical research interest is breast cancer in very young age women, development of nomograms for surgical decision, mammographic density, neoadjuvant hormonal therapy, and breast MRI, etc. He studied and practiced a variety of oncoplastic surgical skills to improve the cosmetic outcome and quality of life of breast cancer patients.
Dr. Han also participated in basic and translational research projects. His current interest is to discover driver gene and mutations of breast cancer using Next Generation Sequencing technique. He is also interested in single cell sequencing and circulating tumor cell detection. In parallel, he is carrying out clinical trial and basic research to prove the efficacy of metformin and its derivatives as a breast cancer treatment. He has been collaborating with world-wide major institute, such as Stanford University, Dana-Farber Cancer Institute, UCLA, and Kyoto University.
Dr. Naoki Hayashi started his carrier as a general surgeon at St. Luke’s International Hospital, Tokyo in 2000. After completion of fellowship in department of Breast Surgical Oncology, he has been a visiting scientist in the department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas, from 2008 to 2011. He gained Ph.D. from Second Department of Pathology, Showa University School of Medicine. Dr. Hayashi received the current position as a chief of staff in department of Breast Surgical Oncology, St. Luke’s International Hospital from 2017. His main research interest is assessment or prediction of response to treatment, bone metastasis from breast cancer, and oncoplastic surgical technique. He is carrying out a multicenter clinical trial as a principal investigator to assess the complete response to preoperative chemotherapy.
Chiun-Sheng Huang, MD, PhD, MPH
Chiun-Sheng Huang is the professor and chairman of Surgery at the National Taiwan University Hospital and National Taiwan University College of Medicine. He is also the director of Breast Care Center. He had been the president of the Breast Cancer Society of Taiwan and is currently the chair of Taiwan Breast Cancer Consortium, an academic research organization focusing on clinical trials. His areas of research also include: ultrasound in breast cancer screening and axillary staging, computer-aided diagnosis of breast ultrasound, and development of new biomarkers as prognostic factors of breast cancer.
Dr. Shigeru Imoto is a professor at the Department of Breast Surgery, Kyorin University School of Medicine. His interest is a minimally invasive therapy of breast cancer. He is the president of the Japanese Society for Sentinel Node Navigation Surgery, a principle investigator of the Federation of Asian Clinical Oncology and a council of Breast Surgery International.
Hiroji Iwata, MD, PhD
Hiroji Iwata is Vice Director and Chief of Breast Oncology at Aichi Cancer Center Hospital, He is also a Clinical Professor at Nagoya City University Medical School.
He is an author of over 100 publications on a wide range of subjects in the treatment of early stage and metastatic breast cancer. He is a director of Breast Cancer Study Group in Japan Clinical Oncology Group (JCOG), a steering committee member in many global clinical trials and also the Japanese coordinating investigator in global investigator driven registration trial (Penelope study).
Dr. Wolfgang Janni is currently full professor and director of the Department Obstetrics and Gynecology of the University of Ulm, Germany. He has been appointed to this position in October 2012, after working as full professor and director of the Department Obstetrics and Gynecology of the Heinrich-Heine-University Duesseldorf, Germany, from 2008 until 2012. He received the credentials for professorship at Munich University in 2015, but decided to stay in Ulm.
Following several internships in major medical institutions, including the Yale University, the University of Michigan and New York University, Doctor Janni received his medical training at the LMU-University in Munich. He is board certified gynaecologist, with board certified subspecialities in gynaecological oncology and breast cancer, as well as perinatal medicine. Doctor Janni was appointed Junior Professor of the Department for Gynaecology and Obstetrics of the General Hospital of the Ludwig-Maximilians-University, Munich, in June 2003.
Doctor Janni’s two main fields of research include the relevance of the detection of disseminated tumor cells in the bone marrow of breast cancer patients, and also clinical research. He developed the protocol for the ADEBAR-Study and was principal investigator of the SUCCESS-A/B/C-Trials, clinical phase III studies comprising more than 10,000 primary breast cancer patients with extensive translational research programs. Doctor Janni is currently sponsoring two phase III trials (Detect III – V) in metastatic breast cancer
His research received numerous international awards, including those of ASCO, AACR and SABCS. He is author and co-author of 213 publications in peer-reviewed journals, including the NEJM, JCO and CANCER, and is member of several editorial boards of reknown peer reviewed journals
Hidetaka Kawabata M.D.
Main Titles
Director, Department of Breast and Endocrine Surgery, Toranomon Hospital
Associate Professor, Department of Surgery, the University of Tokyo
Board Member JBCRG (Japan Breast Cancer Research Group)
Degree-Granting Education
1988 Faculty of Medicine, the University of Tokyo, Tokyo, Japan, MD, Medicine
Postgraduate Training
7/1992-6/1994 Clinical Fellowship, Second Department of Surgery, the University of Tokyo
12/1989-6/1992 Clinical Residency,Department of Surgery, Tokyo Metropolitan Police Hospital
6/1988-11/1989 Clinical Residency ,Second Department of Surgery, the University of Tokyo
Experience
9/2006-present Director, Department of Breast and Endocrine Surgery, Toranomon Hospital
8/1998-8/2006 Associate Director, Department of Surgery, JR Tokyo General Hospital
1/1997-7/1998 Assistant Professor, Second Department of Surgery, the University of Tokyo
7/1994-12/1996 Staff surgeon , Department of Surgery, Tokyo Kyosai Hospital
Board Certifications
Board-certified doctor, the Japan Breast Cancer Society
Board-certified doctor, Japan Surgical Society
Professional Societies and Committees
Japan Surgical Society
Japan Surgical Association
The Japan Breast Cancer Society
Japan Society of Clinical Oncology
American Society of Clinical Oncology
Hiromitsu Jinno
Education:
1987 M.D., cum laude, Keio University School of Medicine
1997 Ph.D., Keio University School of Medicine
Professional Training and Employment:
2015-Present Professor, Department of Surgery, Teikyo University School of Medicine, Tokyo
2014-2013 Associate professor, Department of Surgery, Keio University School of Medicine, Tokyo
2013-2006 Instcuctor, Department of Surgery, Keio University School of Medicine, Tokyo
2001-2005 Associate Director in Breast Service, Department of Surgery, Keio University School of Medicine, Tokyo
1998-2001 Associate Director in Department of Surgery, Tachikawa Hospital, Tokyo
1996-1998 Post-doctoral Research Fellow Department of Surgery, Cornell University, NY, USA
1993-1996 Medical Staff in Department of Surgery, National Saitama Hospital, Saitama
1992-1993 Chief Resident in Department of Surgery, Keio University School of Medicine, Tokyo
1990-1992 Senior Resident in Department of Surgery, Keio University School of Medicine, Tokyo
1989-1990 Medical Staff in Department of Surgery, Ashikaga Red Cross Hospital, Tochigi
1988-1989 Medical Staff in Department of Surgery, Saiseikai Central Hospital, Tokyo
1987-1988 Junior Resident in Department of Surgery, Keio University School of Medicine, Tokyo
1987 passed the Examination of National Board
Societies:
Japanese Society of Surgery
Japanese Cancer Association
Japanese Society of Gastroenterological Surgery
Japan Society for Cancer Therapy
Japanese Breast Cancer Society
American Association for Cancer Research
American Society of Clinical Oncology
European Society of Medical Oncology
Sunil Lakhani is Professor and Head, Discipline of Molecular & Cellular Pathology, The School of Medicine, Head of the Breast Group, The University of Queensland Centre for Clinical Research (UQCCR) and Executive Director Research, Pathology Queensland,
His research team comprising of both scientists and practicing clinicians ensures a translational focus to the research portfolio. His current interests include lobular carcinoma and its variants, tumours with a basal phenotype and mechanisms and therapeutic development of brain and distant metastases. He is a series editor for the WHO Tumour Classification Books and volume editor for the Breast Tumour Classification.
Dr. Ava Kwong is the Clinical Associate Professor, Assistant Dean, Chief of Division of Breast Surgery, The University of Hong Kong (HK) and HK University-Shenzhen Hospital. In 2007, she founded and is Chairman of HK Hereditary Breast Cancer Family RegistryShe was appointed to be a member of the Cancer Coordinating Committee of the “ABC of Breast Disease”, Companion to Specialist Surgical Practice: Breast Surgery, “Up to Date” on-line medical website. She founded and was chairlady of Women’s Surgical Chapter, and become the first women council member of College of Surgeons of Hong Kong and was elected the Chair of the International Committee of the Association of Women Surgeons, USA. She is the first female Clinical Associate Professor in Surgery in Hong Kong
Prof. Bruce Mann is Professor of Surgery at the University of Melbourne and Director of The Breast Service at the Royal Melbourne and Royal Women’s Hospital in Melbourne. He is on the council of Breast SurgANZ, the Scientific Advisory Committee of the ANZ Breast Cancer Trials Group and is past president of the Clinical Oncology Society of Australia. He has been involved in many clinical trials and much clinical and translational research regarding breast cancer, with his main research interest being tailoring treatment to the disease and the patient.
Shinobu Masuda, M.D., Ph.D.
Professional appointment:
Professor
Department of Pathology
Nihon University School of Medicine
Professional carriers:
1985; Graduated from Hirosaki University School of Medicine
1985-1987; Resident, Kensei Hospital
1987-1990; Resident, Division of Pathology, Chuo Hospital
1990-1992; Division of Pathology, Kensei Hospital
Fellow, Department of Pathology, Hirosaki University School of Medicine
1992-1995; Resident, Department of Pathology, Tokai University School of Medicine
1995-1999; Instructor, Department of Pathology, Tokai University School of Medicine
1999-2003; Assistant Professor, Department of Pathology, Tokai University School of Medicine
2003-2011; Associate Professor, Department of Pathology, Tokai University School of Medicine
2011- ; Professor, Department of Pathology, Nihon University School of Medicine
Scientific activities:
Japanese Society of Pathology
Japanese Breast Cancer Society
Japanese Cancer Association
Japanese Society of Clinical Cytology
Japan Society of Histochemistry and Cytochemistry
The Histochemical Society
American Association of Cancer Research
Major research interests:
Mammary epithelial cell differentiation and breast cancer
Cell proliferation mechanism in ER negative breast cancer
Dr. Elizabeth Morris is Chief of the Breast Imaging Service at Memorial Sloan Kettering Cancer Center (MSKCC) and Professor of Radiology at Weill Cornell Medical College and the Larry Norton Endowed Chair. She is a fellow of the American College of Radiology (ACR), Society of Breast Imaging (SBI) and International Society of MR in Medicine (ISMRM). She currently serves as President of the SBI.
Dr. Morris graduated summa cum laude from the University of California Davis and received her medical degree from the University of California, San Francisco (UCSF). She completed her residency at Cornell University Medical College and breast imaging fellow ship at MSKCC.
Her research focus is on how best to use newer techniques such as MRI for early breast cancer detection and to improve the workup of breast lesions. In collaboration with her colleagues, she has written over 130 papers, chapters, and books about breast disease with an emphasis on the use of MRI. She has lectured widely both nationally and internationally at over 300 conferences. Currently, she chairs the MR section of the ACR BIRADS® Lexicon. She has authored a book “Breast MRI: Diagnosis & Intervention.” Her recent research efforts have involved looking at imaging biomarkers to assess risk and treatment response.
Dr. Stacy Moulder completed her fellowship in Hematology/Oncology at the Vanderbilt-Ingram Cancer Center, where she also obtained a Masters of Science in Clinical Investigation. She is a medical oncologist who exclusively sees breast cancer patients and has been appointed within the Breast Medical Oncology program for 10 years at MD Anderson Cancer Center, most recently as the Chief of the Section of Clinical Research. Through this appointment, she maintains a research interest in drug development with novel targeted therapies for the treatment of triple negative breast cancer, predominately as targeted therapy trials for the treatment of metastatic breast cancer or neoadjuvant trials in patients with localized, chemotherapy insensitive disease. Her research interests are focused on the mesenchymal subtype of TNBC, which includes metaplastic breast cancer, a particularly aggressive, chemotherapy refractory form of TNBC that has a high frequency of aberrations in PI3K/Akt/mTOR pathway and has demonstrated response to mTOR inhibition in combination with chemotherapy.
Dr. Seigo Nakamura gained his medical degree in 1982 from Chiba University. He started his career as general surgeon at St. Luke’s International Hospital in Tokyo, Japan after graduation. After 28-years service at St.Luke’s International Hospital, he has moved to Showa University School of Medicine. Currently, Dr. Nakamura is Professor and Chairman, Department of Surgery, Division of Breast Surgical Oncology and Director, Breast Center of Showa University Hospital. He is also Chairman of the Board of Directors in the Japanese Breast Cancer Society. He has dedicated himself to clinical practice and clinical trials on breast cancer. Dr. Nakamura has focused on genetic diagnosis and tailor treatment.
Noriaki Ohuchi, MD, PhD, graduated Tohoku University School of Medcine in 1978, and received PhD degree in 1984. From 1984 to 86 he was assigned as a fellow, National Cancer Institute, NIH, USA. He was appointed as a professor of Tohoku University in 1999, desrved as Vice Director in 2002-04, Director of Cancer Center in 2011-12, University Hospital, and Dean of Graduate School of Medicine from 2012.
Professor Ohuchi covers many reseach fields including oncology, surgery, molecular biology and cancer screening with more than 400 original articles. In summarizing activities as a chief investigator or chairman, the following will be selected, e.g., National breast cancer screening programs by Ministry of Health Labour and Welfare (MHLW,1995-present), Nano-biotechnology projects by MHLW (2002-08) and by Ministry of Education, Culture, Sports, Science and Technology (MECSST 2002-11) and by New Energy and Industrial Technology Development Organization (NEDO). He also organized the NIH-Japan-JSPS Symposium in Sendai, Japan 2013, and in Bethesda, USA 2014.
The Japan Strategic Anti-cancer Randomized Trial (J-START) is one of his representative projects which was supported by MHLW 2007-14, by AMED 2015-present. The primary endpoints of J-START assesed the efficacy of mammography with adjunctive ultrasonography in improving sensitivety and detection rates of early breast cancers in the Lancet, 387: 341-348. 2016
Prof. Yasuhiro Ogawa is Director of Hyogo Prefectural Kakogawa Medical Center, Hyogo, Japan Honorary Observer of the Royal Marsden Hospital in London, the United Kingdom Professor emeritus of Kochi University, Kochi, Japan Visiting Professor of Kobe University, Hyogo, Japan Former Program Officer of Japan Society for the Promotion of Science Board Certified Radiation Oncologist Reference 1. Ogawa Y. Paradigm shift of radiation biology/radiation oncology – Exploitation of “the H2O2 effect” for radiotherapy using low-LET (linear energy transfer) radiation such as X-rays and high-energy electrons.
Dr.P. Raghu Ram is one of the youngest Surgeons from India to be conferred PADMA SHRI (2015) – one of the most coveted civilian awards bestowed by the Govt. of India. He has achieved the rare distinction of obtaining the prestigious FRCS from all four Royal Colleges in British Isles – London, Edinburgh, Glasgow& Ireland & FACS from American College of Surgeons, at a very young age. He conceived, designed & established Indian Subcontinent’s FIRST free standing, purpose built and comprehensive Centre for Breast health in 2007 – KIMS-USHALAKSHMI Centre for Breast Diseasesat Krishna Institute of Medical Sciences (KIMS) in Hyderabad (India). He also established Ushalakshmi Breast Cancer Foundation during the same year. To honour Dr. Ushalakshmi’s struggle (Dr Raghu Ram’s mother) in the fight against breast cancer, the Breast Centre at KIMS & the Foundation bear her name.
Within a short span of seven years, Dr Raghu Ram has made extraordinary contribution at empowering people in India about the importance of early detection of breast cancer through a number of unique & innovative initiatives. Equally, hehas been working with a missionary zeal at bringing about revolutionary changes to Breast healthcare in India. In 2011, Dr Raghu Ram’s proposal to establish India’s FIRST dedicated Society for Surgeons practicing the art & science of Breast Disease was seconded by Surgeons practicing breast surgery from across the Country. In the fullness of time, the newly formed Association of Breast Surgeons of India (ABSI) will endeavor to standardize breast healthcare, and equally, pave the way to establish Breast Surgery as a Subspecialty in India.
Prof. Akihiko Suzuki is Professor of Breast and Endocrine Surgery at the Tohoku Medical and Pharmaceutical University in Sendai, Japan. He started his carrier as a general surgeon in 1992, then he gained Ph.D. in 2000 from Tohoku University. He engaged in not only surgical treatment of breast cancer, but also study for quality control of breast cancer screening. He is one of the core investigators of the Japan Strategic Anti-cancer Randomized Trial (J-START) that is the RCT to assess the efficacy of adjunctive ultrasonography in mammography screening.
Prof. Alastair Thompson graduated from the University of Edinburgh, UK with Distinction in Surgery and subsequently trained as a Clinician Scientist and Fellow of the Royal College of Surgeons of Edinburgh. In 2014 he moved from the position of Professor of Surgical Oncology, Clinical Lead for the Dundee Cancer Centre/Experimental Cancer Medicine Centre and Foundation Director of the Clinical Research Centre, Dundee, UK to the Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center in Houston, Texas, specializing in breast cancer.
Achievements to date include setting up and chairing the Breast Cancer Campaign Breast Tissue Bank Board for the UK and Eire, leading the 12,000 patient UK National Audit of Screen Detected DCIS and, for 5 years to 2014, chairing the UK National Cancer Research Institute, Breast Clinical Studies Group (with oversight of 120 academic and commercial clinical studies in breast cancer). He actively contributes to a range of clinical trials in the prevention, early detection and therapy of breast cancer. He remains as UK Chief Investigator for a number of key trials including MINDACT, MA32 and SOLE and continues to chair the data monitoring committees and trials steering groups for several phase II drug trials and phase III surgical trials respectively in the UK.
Active in translational laboratory research, he built a breast cancer research program over 15 years in Dundee, including a xenograft program and tissue banking facility with a focus on the p53 network and drug development. He has successfully supervised 20 PhD or research MD students and currently has 4 students completing PhDs. The impact of over 200 peer reviewed research papers has included global firsts demonstrating the effect of drugs in vivo in animal models and in human cancers.
He continues to provide leadership in trials and clinical translational research with colleagues in Europe and Australasia while establishing clinical trials and laboratory collaborations in the US, through membership of the American Society of Clinical Oncology, American Association of Cancer Research, South West Oncology Group and Translational Breast Cancer Research Consortium.
Dr. Masakazu Toi graduated in 1982 from Hiroshima University School of Medicine with his Medical Doctorate and in 1988 with his Ph.D. He studied on tumor angiogenesis at the Institute of Molecular Medicine of Oxford University, UK from 1990 to 1992. He was appointed to the Department of Clinical Oncology, John-Radcliffe Hospital of Oxford University as an academic visitor as well. From 1992 to 2007, Dr. Toi worked for Tokyo Metropolitan Cancer and Infectious Disease Center. He was appointed to a director of Surgery and also to a director of Clinical Trial Department. He was engaged in the care of breast cancer patients, laboratory researches and clinical trials. In 2000, he studied at Department of Breast Medical Oncology, Dana-Farber Cancer Institute of Harvard University as a Yamagiwa-Yoshida fellow. Dr. Toi has been appointed to be a visiting professor of Drug Delivery System Center, Tokyo Science University. Since 2007 Dr. Toi has been appointed to Professor of Breast Surgery at the Graduate School of Medicine, Kyoto University, Japan and Director of the Breast Cancer Unit, Kyoto University Hospital. Dr. Toi is passionate in his study of cancer, particularly breast cancer. He is keen on researches that translate basic science into clinical study. He is involved in various innovative research projects on the develop¬ment of new diagnostics and therapeutics. He serves as an editorial board member of multiple academic journals and has authored or co-authored over 450 articles. He has been appointed to Deputy Director of the Society-Academia Collaboration for Innovation of Kyoto University from 2016.
Hitoshi Tsuda graduated National Defense Medical College (NDMC) in 1984 and worked for National Cancer Center (NCC) between 1986 and 2000, as researcher. From 2000 to 2008, he worked for NDMC as an assistant professor and, thereafter, moved to NCC hospital as the chief doctor of the Pathology Division. From 2013, he moved again to the present position in NDMC. His study fields are quality improvement of pathological diagnosis in practice and in clinical studies, novel biomarkers, and mechanism of the genesis of cancers.
Koichiro TSUGAWA, M.D., Ph.D.
EDUCATIONDegree-Granting Education- Kanazawa University School of Medicine, Kanazawa, JAPAN, MD, 1987, Doctor of Medicine
– Kanazawa University Graduate School of Medical Sciences, Kanazawa, JAPAN, PHD, 1993, Surgical OncologyPostgraduate Training- Clinical Residency, Surgery, Kanazawa University Hospital, Kanazawa, JAPAN, 5/1987-3/1988
– Clinical Fellowship, General and Gastrointestinal Surgery, Kanazawa University Hospital, Kanazawa, JAPAN, 4/1988-3/1993EXPERIENCE/SERVICE
– Associate Professor, Department of Surgery, Kanazawa University Hospital, Kanazawa, JAPAN, 1997-2005
– Associate Director of breast surgical oncology, Department of Breast Surgical Oncology, Breast Center, St. Luke’s International Hospital, Tokyo, JAPAN, 2005-2010
– Professor and Chairman, Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, September 2010-
CREDENTIALS
Board Certification
Japanese Board of Surgery- Generalist, 6377, 1991-.
Japanese Board of Surgery- Specialist, 1903028, 2000-.
Japanese Board of Surgery- Instructor, S005981, 2000-.
Japanese Board of Breast Cancer- Specialist of Breast disease, 0529, 2006-.
Takayoshi Uematsu, Japan
Associate Professor Nicholas Wilcken MB BS, PhD, FRACP,
Nicholas Wilcken is Director of Medical Oncology at the Crown Princess Mary Cancer Centre Westmead, Senior Staff Specialist at Nepean Hospital, and Associate Professor of Medicine, University of Sydney, Australia.
Medical oncology training was at Royal Prince Alfred Hospital, Sydney, followed by a PhD in breast cancer cell cycle control at the Garvan Institute, Sydney.
His clinical interests are in breast cancer and colo-rectal cancer. Research interests include translational oncology, systematic reviews and breast cancer clinical trials.
He is currently the Co-ordinating Editor of the Cochrane Collaboration’s Breast Cancer Group and Chair of the ANZ Breast Cancer Trials Group, Scientific Advisory Committee. He has been an invited expert panel member for the last two St Gallen Early Breast Cancer Consensus Conferences in Switzerland and is a member of the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group, based in Oxford, UK.
Dr. Hideko Yamauchi, Director of the Department of Breast Surgical Oncology and Vice President of St. Luke’s International Hospital in Tokyo, received her medical education at Juntendo University in Tokyo, Japan. After she completed her surgical residency at St. Luke’s International Hospital, she underwent further training in the United States as a researcher and an instructor at the Dana-Farber/Harvard Cancer Center and at Georgetown Lombardi Comprehensive Cancer Center. She also completed a clinical surgical residency and clinical fellowship at the University of Hawaii, and a clinical fellowship at H. Lee Moffitt Cancer Center & Research Institute. Dr. Yamauchi returned to St. Luke’s International Hospital in 2009, and received the position as the Director of the Breast Center in 2010. She was then appointed as the Vice President of the same hospital in April of 2017. She has been working at her “home ground” to develop “a living compassionate team” of clinicians, researchers, and patients.
Professor Jin Zhang
·Professor, Tianjin Medical University.
·Deputy Director, Tianjin Breast Cancer Research and Treatment Center.
·Director of department III of breast surgery, Tianjin Medical University Cancer Hospital.
·Vice Chairman, Chinese Anti-Cancer Association Society of Breast Cancer.
·Standing Commissioner, Chinese Medical Association of Oncology.
·Deputy Director, China Medical Women Association of Breast Disease Research Center.
·Vice Chairman, Chinese College of Surgeons of Breast Cancer.
·Active Member, American Society of Clinical Oncology.
·Active Member, American Society of Hematology.
·Active member, American Association for Cancer Research.